1. Improving skin cancer management with ARTificial intelligence: A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting.
- Author
-
Felmingham C, Pan Y, Kok Y, Kelly J, Gin D, Nguyen J, Goh M, Chamberlain A, Oakley A, Tucker S, Berry W, Darling M, Jobson D, Robinson A, de Menezes S, Wang C, Willems A, McLean C, Cranwell W, Adler N, Wada M, Foley P, Brack J, Cumming S, Byars G, Bowling A, Ge Z, Haskett M, Wolfe R, and Mar V
- Subjects
- Humans, Artificial Intelligence, Administration, Cutaneous, Dermatology, Skin Neoplasms diagnosis, Melanoma diagnosis
- Abstract
Competing Interests: Conflicts of interest C Felmingham was supported by a Monash University Research Training Program Scholarship. Y Pan has previously reported for MoleMap Ltd. A Chamberlain was a reporting teledermatologist for MoleMap Ltd from 2009 to 2010. A Chamberlain has honoraria from Proctor & Gamble, Schering-Plough, CSL, Leo-Pharma; a consulting/advisory role for L'Oreal (La Roche Posay); and is on the Speakers Bureau for Novartis, Janssen, HealthCert International, Cancer Council of Victoria, Merck Sharp & Dohme. A Oakley is a diagnosing consultant for MoleMap Ltd; and was involved in another study of the MoleMap AI system (abstract published https://www.iproc.org/themes/1158-9th-world-congress-of-teledermatology-imaging-and-ai-for-skin-diseases-abstracts-2021). S Tucker is a diagnosing consultant for MoleMap Ltd and Dermatology Solutions. A Robinson is a sub-Investigator for Dermira, Galderma, Pfizer, Arcutis, Bristol Myers Squib, Leo Pharma, Argenx, Genesis Care; has had sponsored conference attendance from Lilly, and Janssen was on the steering committee for conference for Novartis; and on the Advisory Board for Lilly. P Foley has received grant support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Sanofi, and Sun Pharma; has served as an investigator for AbbVie, Amgen, Arcutis, Argenx, Aslan, AstraZeneca, Boehringer Ingelheim, Botanix, Bristol-Myers Squibb, Celgene, Celtaxsys, CSL, Cutanea, Dermira, Eli Lilly, Evelo, Galderma, Genentech, Geneseq, GlaxoSmithKline, Hexima, Janssen, Kymab, Leo, Merck, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Reistone, Roche, Sanofi, Sun Pharma, Teva, UCB Pharma, and Valeant; has served on advisory boards for AbbVie, Amgen, Aslan, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Leo, Mayne Pharma, Merck, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Valeant; has served as a consultant for Aslan, Bristol-Myers Squibb, Eli Lilly, Galderma, GenesisCare, Hexima, Janssen, Leo Pharma, MedImmune, Mayne Pharma, Novartis, Pfizer, Roche, and UCB Pharma; has received travel grants from AbbVie, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sun Pharma, and Sanofi; and has served as a speaker for or received honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Sun Pharma, and Valeant. A Bowling is a shareholder, founder and consultant to MoleMap Ltd. Z Ge has received personal fees from MoleMap Ltd. M Haskett has received personal fees from MoleMap Ltd and is a shareholder in MoleMap Ltd. V Mar is supported by a National Health and Medical Research Council Early Career Fellowship; and has honoraria from Novartis, Merck, Bristol-Myers-Squibb, Janssen, and Eli Lily; and has had sponsored conference attendance from L'Oreal.
- Published
- 2023
- Full Text
- View/download PDF